23 Oct 19 | 10:20
Aurobindo Pharma Ltd
Exchange Received Time
Exchange Disseminated Time
Announcement under Regulation 30 (LODR)-Joint Venture |
8/30/2019 5:42:56 PM
We inform you that our wholly owned subsidiary, Helix Healthcare B.V, Netherlands, has on August 29, 2019 entered into an agreement with Shanghai LongJin Investment Company Ltd., China and Sveva Capitals, Hongkong to establish a Joint Venture Company in China under the name of 'Longxiang Pharma Taizhou Co Ltd'., for development, manufacturing, marketing and sale of pharmaceutical products for China excluding Taiwan, Hongkong and Macau.
The disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Part A of Schedule III of the aforesaid regulations, is attached as 'Annexure A'.
Copyright@ 2015. All Rights Reserved.
23 Oct 19|10:20 (IST)